Advanced Plant Pharmaceuticals, Inc. Files Composition Patent for Sinusol
Monday September 8, 1:14 pm ET
Patent Builds on Company's Intellectual Property Portfolio
NEW YORK--(BUSINESS WIRE)--Sept. 8, 2003--Advanced Plant Pharmaceuticals, Inc., (OTCBB:APPI - News) a company that utilizes whole plants through a proprietary (patent pending) manufacturing process to develop nutraceuticals and supplements, has announced the filing for a composition patent for the formula of APPI's homeopathic allergy and sinus spray, Sinusol(TM) with the United States Patent and Trademark Office (www.uspto.gov).
This patent filing for Sinusol(TM) will enhance Advanced Plant Pharmaceutical's patent portfolio and set the stage for increased shareholder value going forward. By building an intellectual property asset portfolio, APPI demonstrates the unique nature of its products along with building barriers to entry by any competitor. With the recently announced expansion of distribution of Sinusol(TM) into Asia, it was deemed advisable to protect APPI's rights to the unique formulation of Sinusol(TM).
According to the Asthma and Allergy Foundation of America (http://www.aafa.org), the allergy and sinus market is large, with more than 60 million people in America with asthma or allergies. Chronic sinusitis, sinusitis that persists for at least 3 weeks, affects an estimated 32 million people in the United States. Allergic rhinitis (allergic nasal symptoms) affects more than 20% of all Americans. In the United States alone, the cold, allergy and sinus medicine market totals $1.86 Billion annually.
Sinusol(TM) is formulated to be a gentle, non-habit-forming, non-drowsy solution that can be used in conjunction with cold, allergy and sinus medications. Sinusol(TM) offers fast, safe and effective temporary relief of sinus pain and nasal congestion for hours without drowsiness. Additional uses include sore throats and as a gargle for hoarseness and laryngitis.
For additional information on APPI, please visit the Company's Web site at www.advancedplantpharm.com.
FORWARD-LOOKING STATEMENTS:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described. Risks and uncertainties include, but are not limited to, clinical development, clinical trials, regulatory approvals in targeted market countries, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company and/or other factors, which are outside the control of the Company.
--------------------------------------------------------------------------------
Contact:
APPI
Sam Berkowitz, 212-695-3334
or
LC Group
404-261-1196 |
